AERI
$17.01
Aerie Pharmaceuticals
($1.72)
(9.18%)
AERI
Earnings Whisper ®
N/A
1st Quarter March 2020
Consensus:  ($0.71)
Revenue:  N/A
Thursday
May 21
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Thursday, February 20, 2020

What do you expect when AERI reports earnings?
Beat
Meet
Miss

Where is AERI's stock price going from here?
Up
Flat
Down
Stock chart of AERI
Analysts
Summary of analysts' recommendations for AERI
Score
Grade
Pivots
Resistance
$19.82
$19.51
$19.12

$18.81

Support
$18.42
$18.11
$17.72
Tweet
Growth
Description
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's lead Dual- Action product and Triple-Action products are under developmental stages. Aerie Pharmaceuticals, Inc. is headquartered in Bedminster, New Jersey.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsInterCeptZoetisJohnson & JohnsonMylanUltragenyx PharmaceuticalBristol-Myers SquibbAlkermes